PILOT STUDY OF INTRAVITREAL INJECTION OF DICLOFENAC FOR TREATMENT OF MACULAR EDEMA OF VARIOUS ETIOLOGIES

Abstract

Up to 8 weeks, intravitreal diclofenac treatment of eyes with macular edema of various etiologies yielded prominent improvement in visual acuity but was not associated with a significant decrease in central macular thickness. No toxic effect of intravitreal diclofenac was observed.